Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Robert L. Yauch(Gene Therapy Laboratory), Michael Berlin(Arvinas (United States))
Cited by 2
Related Papers
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
|Nature Communications|2022|125
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
|Nature Communications|2025|11